Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Background Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plasm...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Critical care (London, England) Ročník 26; číslo 1; s. 164 - 8
Hlavní autoři:	Boyle, Andrew James, Ferris, Peter, Bradbury, Ian, Conlon, John, Shankar-Hari, Manu, Rogers, Angela J., O’Kane, Cecilia M., McAuley, Daniel F.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 07.06.2022 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Acute respiratory distress syndrome Biological markers Carrier Proteins Clinical trials Complications and side effects Confidence intervals Critical care Critical Care Medicine Cytokines Drug therapy Emergency Medicine Health aspects Humans Inflammasome Inflammasomes Intensive Interleukin-18 Medicine Medicine & Public Health Mortality Patient outcomes Patients Personalised medicine Personalized medicine in the ICU Plasma Precision medicine Regression analysis Respiratory distress syndrome Respiratory Distress Syndrome - drug therapy Risk factors Sepsis Simvastatin Simvastatin - pharmacology Simvastatin - therapeutic use Statins Testing United Kingdom United Kingdom > UK Germany Acute respiratory distress syndrome Inflammasome Personalised medicine Interleukin-18 Simvastatin
ISSN:	1364-8535, 1466-609X, 1364-8535, 1466-609X, 1366-609X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!